Lycia Therapeutics, Inc. Common Stock (LYCA) stock forecast & analysis
30.00
NasdaqGS · USDDelayed by 15 minutes
Up: +12.00, +66.7%
1 analysis
Latest analysis: · verdict locked
- Open
- 28.55
- Previous close
- 18.00
- Day range
- 22.19 – 36.49
- 52-week range
- 22.19 – 36.49
- Volume (shares)
- 2.29M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 52.09M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- Not available
- Market cap
- 1.56B
Market Scanner’s AI analysis of Lycia Therapeutics, Inc. Common Stock (LYCA), updated October 2026: Lycia Therapeutics' IPO valuation and revenue decline were key discussion points in recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Lycia Therapeutics, Inc. Common Stock (LYCA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Lycia Therapeutics' IPO valuation and revenue decline were key discussion points in recent analyses.
Recent analyses examined Lycia Therapeutics' (LYCA) debut trading performance following an upsized IPO, noting its valuation as a central market discussion point. The reports also covered a notable decrease in annual revenue between 2024 and 2025, alongside significant operating and net losses, while tracking the company's cash position.
LYCA news & sentiment
Market sentiment surged following Lycia Therapeutics' IPO, with its debut trading performance and valuation becoming key discussion points. News coverage highlighted the biotech IPO's success within a broader trend of strong performance in the sector.
Fundamentals
Lycia Therapeutics' recent analyses covered a significant decline in annual revenue between the last two fiscal years, accompanied by substantial operating and net losses. The company's cash position was noted, alongside its market capitalization and current stock price following its IPO.
Factors discussed — upside
- Upsized $317.5 million IPO
- Company cash position of $124,321,000 USD as of June 30, 2026
Factors discussed — risks
- Annual revenue decrease from $14,936,000 USD in 2024 to $6,741,000 USD in 2025
- Significant operating losses in 2025 (-$39,878,000 USD) and 2024 (-$32,533,000 USD)
- Net loss of -$36,460,000 USD in 2025 and -$26,503,000 USD in 2024
- IPO performance
- Valuation
- Revenue trends
- Profitability
Summary updated .
Analyses
Recent LYCA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-26 LYCA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Lycia Therapeutics, Inc. Common Stock?
- The company successfully completed an upsized $317.5 million IPO, and as of June 30, 2026, held a cash position of $124,321,000 USD.
- What are the risks for Lycia Therapeutics, Inc. Common Stock?
- Annual revenue saw a significant decrease from $14,936,000 USD in 2024 to $6,741,000 USD in 2025, accompanied by substantial operating and net losses in both 2025 and 2024.
- Is Lycia Therapeutics, Inc. Common Stock bullish or bearish?
- Recent AI analyses of Lycia Therapeutics, Inc. Common Stock examined factors on both sides. Discussed upside: The company successfully completed an upsized $317.5 million IPO, and as of June 30, 2026, held a cash position of $124,321,000 USD. Discussed risks: Annual revenue saw a significant decrease from $14,936,000 USD in 2024 to $6,741,000 USD in 2025, accompanied by substantial operating and net losses in both 2025 and 2024. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Lycia Therapeutics, Inc. Common Stock?
- Market sentiment surged following Lycia Therapeutics' IPO, with its debut trading performance and valuation becoming key discussion points. News coverage highlighted the biotech IPO's success within a broader trend of strong performance in the sector.
- How does Market Scanner analyse Lycia Therapeutics, Inc. Common Stock?
- Every analysis of Lycia Therapeutics, Inc. Common Stock runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Lycia Therapeutics, Inc. Common Stock?
The company successfully completed an upsized $317.5 million IPO, and as of June 30, 2026, held a cash position of $124,321,000 USD.
What are the risks for Lycia Therapeutics, Inc. Common Stock?
Annual revenue saw a significant decrease from $14,936,000 USD in 2024 to $6,741,000 USD in 2025, accompanied by substantial operating and net losses in both 2025 and 2024.
Is Lycia Therapeutics, Inc. Common Stock bullish or bearish?
Recent AI analyses of Lycia Therapeutics, Inc. Common Stock examined factors on both sides. Discussed upside: The company successfully completed an upsized $317.5 million IPO, and as of June 30, 2026, held a cash position of $124,321,000 USD. Discussed risks: Annual revenue saw a significant decrease from $14,936,000 USD in 2024 to $6,741,000 USD in 2025, accompanied by substantial operating and net losses in both 2025 and 2024. These are descriptive observations, not a recommendation.
What is the latest sentiment on Lycia Therapeutics, Inc. Common Stock?
Market sentiment surged following Lycia Therapeutics' IPO, with its debut trading performance and valuation becoming key discussion points. News coverage highlighted the biotech IPO's success within a broader trend of strong performance in the sector.
How does Market Scanner analyse Lycia Therapeutics, Inc. Common Stock?
Every analysis of Lycia Therapeutics, Inc. Common Stock runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh LYCA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.